US7078058B2 - Corticosteroid-containing pharmaceutical composition - Google Patents

Corticosteroid-containing pharmaceutical composition Download PDF

Info

Publication number
US7078058B2
US7078058B2 US10256754 US25675402A US7078058B2 US 7078058 B2 US7078058 B2 US 7078058B2 US 10256754 US10256754 US 10256754 US 25675402 A US25675402 A US 25675402A US 7078058 B2 US7078058 B2 US 7078058B2
Authority
US
Grant status
Grant
Patent type
Prior art keywords
composition
active
alcohol
preferably
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US10256754
Other versions
US20030118511A1 (en )
Inventor
Julie Irene Jones
Anthony Richard Baker
Neil Graham Halls
Peter Watmough
Peter Marriott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel West Coast LLC
Original Assignee
Soltec Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/945Foam

Abstract

A foamable pharmaceutical composition comprising a corticosteroid, a quick-break foaming agent, a propellant and a buffering agent, sufficient to buffer the composition to within the range of pH 3.0 to 6.0 is disclosed. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent. Due to the nature of the compositions of the invention, they are especially well-suited for use in the treatment of various skin diseases, and in particular, in the treatment of scalp psoriasis.

Description

CROSS REFERENCE TO RELATED APPLICATIONS AND CLAIM FOR FOREIGN PRIORITY

This application is a continuation of U.S. patent application Ser. No. 09/624,473 (now abandoned), filed Jul. 24, 2000 as a divisional of U.S. patent application Ser. No. 08/913,144 (now U.S. Pat. No. 6,126,920), filed Jan. 12, 1998 as a §371 United States National Phase filing of PCT/GB96/00490 (expired), filed Mar. 1, 1996 claiming priority from GB 9504265.1, filed Mar. 3, 1995. The entire contents of each of the earlier applications is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to an improved pharmaceutical composition for the topical administration of corticosteroid-active substances to the skin of a subject.

BACKGROUND OF THE INVENTION

Corticosteroids, particularly in the form of ester compounds, are used, inter alia, in the treatment of skin diseases in humans, such as, for example, eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. Formulations containing such active substances have conventionally been applied to the skin site in the form of alcoholic solution, lotions or creams. However, there is a high degree of ineffectiveness with such formulations. Lotions and creams are generally too viscous o allow efficient penetration of the active ingredient to the epidermis, and solution have a tendency to evaporate before penetrating the epidermis. In addition, convention cream bases are irritating to the ski, particularly over the often long exposure that is required, and the fluidity of lotions often makes the physical application difficult to control. Moreover, it is necessary to rub such formulations into the target site to improve the penetration of the active substance into the epidermis, an action which itself produces irritation.

There has therefore been a very real need in the treatment of skin disorders requiring treatment with corticosteroids for improved formulations which target the most effective corticosteroid to the skin site with improved delivery of the active substance, with decreased inconvenience and irritation, and increased ease of use for the patient.

SUMMARY OF THE INVENTION

The present invention provides an improved composition which addresses these needs.

In one embodiment, the present invention provides a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent.

Such a composition is applied to the skin site (after foaming) as a foam which is a thermophobic (heat sensitive) quick-break foam. On application to the skin, the composition is initially in the form of a mousse-like foam. The quick-break foam slowly breaks down at the skin temperature to a liquid to allow the alcohol and active substance to saturate the treatment site. Such a system provides enhanced penetration of the alcohol and active substance through the epidermis. Because the composition is supplied as a mousse, the semi-rigid behavior of the composite makes it easier to handle and physically control. The foamed composition, when applied, provides a thick ball of foam which disintegrates easily when spread, allowing proper coverage of the skin site to be treated without premature evaporation of the solvent. It has been found important to include a buffering agent in the composition to stabilize the active isomer of the corticosteroid active substance in the complex foamable composition, otherwise the complex interactions within the foamable composition may result in the instability of the more active isomer.

DETAILED DESCRIPTION OF THE INVENTION

Use of a quick-break foaming agent is required in the present invention. Such agents are known. Suitable quick-break foaming agents in the present invention are those described in Australian Patent Number 463216 and Published International Patent Application WO 85/01876. It is generally preferred that the quick-breaking foaming agent comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent. Particularly preferred is a quick-break foaming agent having the following composition:

    • (a) an aliphatic alcohol, preferably in amounts of 40–90% w/w composition, more preferably, 55–70% w/w, and especially preferred, 57–59% w/w;
    • (b) water, preferably in amounts of 10–40% w/w;
    • (c) at least one fatty alcohol, preferably in amounts of 0.5–10% w/w; and
    • (d) a surface active agent, preferably an ethoxylated sorbitan ester (as emulsified), typically in amounts of 0.1–15% w/w.

In the quick-break foaming agent, the fatty alcohol may be chosen from, for example, cetyl, stearyl, lauryl, myristyl and palmityl alcohols and mixtures of two or more thereof. Mixtures of cetyl alcohol and a stearyl alcohol such as octadecan-1-o1 have been found to be particularly preferred; the ratio between these two components may be adjusted to maintain foam viscosity throughout the broadest possible temperature range. In this situation, the stearyl alcohol maintains the viscosity at temperatures above 20° C. whilst cetyl alcohol maintains the viscosity below 20° C.

The aliphatic alcohol may preferably be chosen from methyl, ethyl, isopropyl and butyl alcohols, and mixtures of two or more thereof. Ethanol has been found to be particularly preferred.

Surface active agents utilized in the quick-break foaming agent may preferably be chosen from ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol ethoxylates and fatty alcohol ethoxylates, and mixtures of two or more thereof. Thus, for example, Polysorbate 60 (a mixture of partial stearic esters of sorbitol and its anhydrides copolymerized with approximately 20 moles of ethylene oxide for each mole of sorbitol and its anhydrides) has been found to be particularly preferred. The surface active agent enhances the fatty alcohol solubility in the system and enhances foam formation.

The propellant used may be chosen from conventional aerosol propellants. Thus, one may select the propellant from propane, butane, dichloro difluoro methane, dichloro tetrafluoro ethane, octafluoro cyclobutane, and mixture s of two or more thereof. It is necessary to select a propellant most compatible with the entire system. It is particularly preferred that the propellant be present in amounts preferably of 3–30% w/w, more preferably, 3–10% w/w, and most preferably, 3–5% w/w. The maximum level of propellant will be determined as the amount miscible with the utilized water/aliphatic alcohol ratio. In addition to acting as a propellant, the propellant will also act as a solvent for the fatty acids and active substances in the aqueous/alcoholic system.

It is possible that other additives may be used. Thus, it is preferred to add a humectant to reduce the drying effects of the aqueous aliphatic alcohol. Such a humectant may preferably be present in an amount of 0.1–10% w/w and more preferably 0.5–3.0% w/w. To is particularly preferred that the humectant be propylene glycol, but other humectants such as glycerine, panthenol and sorbitol may also be use.

The composition of the present invention may be used to deliver corticosteroid compounds which have utility in the topical treatment of skin disorders. Thus, for example, the composition of the present invention may be used to deliver the following topically-effective corticosteroid:

alclometasone dipropionate fluclorolone acetonide
amcinonide fluocinolone acetonide
beclomethasone dipropionate fluocinonide
betamethasone benzoate fluocoritin butyl
betamethasone dipropionate fluocortolone preparations
betamethasone valerate fluprednidene acetate
budesonide flurandrenolone
clobetasol propionate halcinonide
clobetasol butyrate hydrocortisone
desonide hydrocortisone butyrate
desoxymethasone methylprednisolone acetate
diflucortolone valerate mometasone furoate
flumethasone pivalate triamcinolone acetonide
and pharmacologically effective mixtures thereof

Compositions according to the invention are especially advantageous for the topical administration to the skin of human subjects of betamethasone and its derivatives, such as betamethasone benzoate, betamethasone dipropionate and betamethasone valerate. It is particularly preferred to use the valerate ester, especially in the treatment of psoriasis.

The corticosteroid active substance is preferably present in an amount o 0.01–1.0% w/w and more preferably, 0.05–0.2% w/w.

In view of the complexity of the composition, it has been found that unexpectedly, in order to ensure stability of the active isomer of the corticosteroid in the composition, and thus to ensure delivery of the most active isomer to the epidermis, it is necessary to buffer the composition by including a suitable buffering agent. Suitable buffering agents are acetic acid/sodium acetate, citric acid/sodium citrate and phosphoric acid/sodium phosphate, and it is desirable generally to buffer the composition to pH 3.0 to 6.0 and preferably, to pH 4.0–5.0. To this end, the buffering agent may preferably be present in an amount of 0.01–1.0% w/w and more preferably 0.05%–0.2% w/w. It is particularly preferred to use a citrate buffer system, and more preferably, anhydrous citric acid/potassium citrate, to buffer the composition to pH 4.5, when betamethasone valerate is used as the active substance; in this case, citrate buffering stabilizes the more active 17-valerate ester over the less active 21-valerate ester in the complex composition and ensures that the most effective form of the active substance is efficiently delivered to the epidermis.

Preparation of the composition may be affected by conventional means, so as to produce a homogeneous solution of fatty alcohol(s) or wax(es), in the alcohol/water base. The relative proportions of the fatty alcohol(s), water/aliphatic alcohol and propellant are conveniently controlled according to conventional means so as o provide a homogeneous clear solution and so as to allow the formation of a suitable quick-break foam. Generally speaking, the fatty alcohol(s), surface active agent, aliphatic alcohol and humectant (when present) are preferably mixed together with the corticosteroid active substance to produce and “alcohol phase”. An “aqueous phase” is preferably produced by mixing the buffering agent and water. These phases are then mixed, preferably in the final container, in the required amounts. The propellant is then added under pressure to produce he composition according to the present invention.

In the case of betamethasone valerate, for example, it is particularly preferred to use a composition comprising cetyl alcohol and octadecan-1-o1 as fatty alcohols, together with Polysorbate 60 surface active agent, with purified water and ethanol as the aliphatic alcohol. The system is preferably buffered with anhydrous citric acid potassium citrate and the propellant is preferably butane/propane. It is generally preferred to choose the proportion of the components to achieve a fixed pressure in the container of around 50–70 psi.

The composition of the present invention may be contained in and dispensed from, a container capable of withstanding the pressure of the propellant gas and having an appropriate valve/nozzle for dispensing the composition as a foam under pressure. If the container is made of metal material likely to suffer corrosion under the action of the composition, the composition may include a corrosion inhibitor as an additive. Thus, the present of a corrosion inhibitor may be necessary if the container is made of tin plate. Suitable corrosion inhibitors include organic acid salts, preferably chosen from sorbic acid, benzoic acid, sodium benzoate and potassium sorbate. If used, the corrosion inhibitor maybe present in amounts of 0.1–15% w/w and more preferably, 0.1–3.0% w/w. In the present invention, aluminum cans are preferred as containers, particularly when utilizing the above-mentioned composition for betamethasone valerate as the corticosteroid active substance; in this case, there is no corrosion problem and there is no need of the inclusion of a corrosion inhibiting agent.

In use, the composition is sprayed, producing a semi-solid (i.e. a foam or mousse) that is suitable for the topical application to the scalp. On application, heat from the skin causes the mousse to break down into liquid form, thus releasing the aliphatic alcohol and corticosteroid active substance which penetrate the skin site, leaving a low amount of residue, many times lower than those obtained when delivering active ingredient from a cream base. This route of administration facilitates the ease of specific local applications, and the composition according to the present invention provides a convenient, controllable and efficient vehicle for delivering active substance to the skin. This gives greater physical control compared to conventional topical corticosteroid formulations, minimizes rubbing of the target site and allows the alcoholic vehicle to penetrate the skin to deliver the active ingredient where it will have the greatest effect.

The composition of the present invention may be used in treating skin diseases that are conventionally treated with corticosteroid active substances. Thus, the composition may be use in the treatment of, inter alia, eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. The composition is especially useful in the treatment of scalp psoriasis in human subjects.

The principals of the present invention are illustrated below by means of the following non-limiting example.

A betamethasone valerate formulation having the following composition was prepared:

Ingredient % w/w
betamethasone valerate .12
cetyl alcohol BP 1.10
octadecan-1-ol BP 0.50
Polysorbate 60 BP 0.4.
ethanol 57.79
purified water 33.69
propylene glycol BP 2.00
citric acid anhydrous BP 0.073
potassium citrate 0.027
butane/propane 4.30
100.000

Alcoholic Phase

Cetyl alcohol (HYFATOL 1698, Efkay Chemicals Limited, London, England), octadecan-1-o1 (HYFATOL 1898, Efkay Chemicals Limited, London, England), Polysorbate 60 (CRILLET 3, Croda Chemicals, North Humberside, England) and ethanol in the appropriate proportions were mixed and heated to about 45° C., with continuous stirring until the mix became clear. Betamethasone valerate BP (Roussel Uclaf, Virtolaye, France) was slowly transferred into the mix, again with continuous stirring until the mix became clear.

Aqueous Phase

Purified water was separately heated to 45° C. and anhydrous citric acid BP and potassium citrate BP transferred to the water, with continuous stirring until dissolved.

The alcoholic and aqueous phases were each filtered through 75μ screens and the required weights filled into a can (epoxy lined aluminum) at room temperature. After attaching a valve, the butane/propane propellant (Propellant P&)) was added to the mix in the can to the required weight, and an actuator added to the valve.

The composition, on being sprayed from the can onto the skin, produces a thermophobic foam which breaks down under heating from the skin to release the active ingredient to the epidermis. The presence of the citrate buffer stabilizes the 17-valerate configuration of the betamethasone valerate over the less active 21-valerate configuration, thus producing a composition which efficaciously delivers the active ingredient to the epidermis and which is particularly suitable for the treatment of psoriasis, especially scalp psoriasis.

Claims (1)

1. A foamable pharmaceutical composition adapted for topical administration having the following composition:
% w/w Betamethasone Valerate 0.120 Cetyl Alcohol BP 1.100 Octadecan-1-ol BP 0.500 Polysorbate 60 BP 0.400 Ethanol 57.790 Purified Water 33.690 Propylene Glycol BP 2.000 Citric Acid Anhydrous BP 0.073 Potassium Citrate 0.027 Butane/Propane 4.300 100.000.
US10256754 1995-03-03 2002-09-27 Corticosteroid-containing pharmaceutical composition Active 2019-04-06 US7078058B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9504265.1 1995-03-03
GB9504265A GB9504265D0 (en) 1995-03-03 1995-03-03 Corticosteroid-containing pharmaceutical composition
PCT/GB1996/000490 WO1996027376A1 (en) 1995-03-03 1996-03-01 Corticosteroid-containing pharmaceutical composition
US08913144 US6126920A (en) 1995-03-03 1996-03-01 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
US62447300 true 2000-07-24 2000-07-24
US10256754 US7078058B2 (en) 1995-03-03 2002-09-27 Corticosteroid-containing pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10256754 US7078058B2 (en) 1995-03-03 2002-09-27 Corticosteroid-containing pharmaceutical composition
US11394848 US20060171898A1 (en) 1995-03-03 2006-03-30 Corticosteroid-containing pharmaceutical composition

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/GB1996/000490 Division WO1996027376A1 (en) 1995-03-03 1996-03-01 Corticosteroid-containing pharmaceutical composition
US08913144 Division US6126920A (en) 1995-03-03 1996-03-01 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
US62447300 Continuation 2000-07-24 2000-07-24

Publications (2)

Publication Number Publication Date
US20030118511A1 true US20030118511A1 (en) 2003-06-26
US7078058B2 true US7078058B2 (en) 2006-07-18

Family

ID=10770568

Family Applications (3)

Application Number Title Priority Date Filing Date
US08913144 Expired - Lifetime US6126920A (en) 1995-03-03 1996-03-01 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
US10256754 Active 2019-04-06 US7078058B2 (en) 1995-03-03 2002-09-27 Corticosteroid-containing pharmaceutical composition
US11394848 Abandoned US20060171898A1 (en) 1995-03-03 2006-03-30 Corticosteroid-containing pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08913144 Expired - Lifetime US6126920A (en) 1995-03-03 1996-03-01 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11394848 Abandoned US20060171898A1 (en) 1995-03-03 2006-03-30 Corticosteroid-containing pharmaceutical composition

Country Status (11)

Country Link
US (3) US6126920A (en)
EP (1) EP0813413B1 (en)
JP (1) JP4557310B2 (en)
KR (1) KR100427492B1 (en)
CN (1) CN1082817C (en)
CA (1) CA2214436C (en)
DE (2) DE69630593D1 (en)
DK (1) DK0813413T3 (en)
ES (1) ES2210349T3 (en)
GB (1) GB9504265D0 (en)
WO (1) WO1996027376A1 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233735A1 (en) * 1998-06-19 2006-10-19 Isabelle Preuilh Method for treating ailments of the scalp
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8760906B2 (en) 2009-11-24 2014-06-24 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor memory device
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
WO2015044879A1 (en) 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Propellant-free topical spray composition of halobetasol
WO2015044857A1 (en) 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Topical spray composition of halobetasol
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2015138650A1 (en) 2014-03-11 2015-09-17 Promius Pharma, LLC Topical corticosteroid compositions
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9364485B2 (en) 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9561240B2 (en) 2012-12-26 2017-02-07 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244089C (en) * 1996-02-19 2009-06-02 Monash University Dermal penetration enhancers and drug delivery systems involving same
FR2745716B1 (en) * 1996-03-07 1998-04-17 Oreal Oil-in-water foaming pressurizable ultrafine
EP0954321B1 (en) * 1996-11-04 2006-01-11 Psiron Ltd Synergistic compositions containing gold and a corticosteroid
EP1692951A1 (en) 1997-10-17 2006-08-23 Connetics Australia Pty Limited Topical antifungal composition
ES2268856T3 (en) 1998-04-22 2007-03-16 Connetics Australia Pty Limited pharmaceutical composition.
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
ES2431330T3 (en) 1998-09-11 2013-11-26 Stiefel Research Australia Pty Ltd Aerosol foam composition
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
US6358541B1 (en) 2000-05-03 2002-03-19 David S. Goodman Topical preparation for the treatment of hair loss
CN1228103C (en) * 2000-09-15 2005-11-23 巴克斯特国际公司 Container for inhalation anesthetic
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
ES2589077T3 (en) * 2002-06-25 2016-11-10 Acrux Dds Pty Ltd Control of the rate of transdermal pharmaceutical compositions using amorphous
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
JP4828404B2 (en) * 2003-01-24 2011-11-30 ステフェル リサーチ オーストラリア プロプライエタリー リミティッド Clindamycin phosphate foam
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050014823A1 (en) * 2003-07-17 2005-01-20 Soderlund Patrick L. Topical anesthetic composition and method of administration
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
WO2005018530A3 (en) 2003-08-25 2005-10-20 Meir Eini Penetrating pharmaceutical foam
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
ES2552936T3 (en) * 2003-12-12 2015-12-03 Otic Pharma Ltd. Compositions for the treatment of disorders in the ear and methods for use thereof
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8003616B2 (en) 2004-04-23 2011-08-23 Albert Rory J Composition for the treatment of ear infections and method
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
WO2007054818A3 (en) 2005-05-09 2008-10-23 Foamix Ltd Foamable vehicle and pharmaceutical compositions thereof
CA2609579C (en) * 2005-05-27 2014-08-19 Taro Pharmaceuticals North America, Inc. Stable liquid desoximetasone compositions with reduced oxidized impurity
ES2447301T3 (en) 2005-06-01 2014-03-11 Glaxosmithkline Intellectual Property Development Limited vitamin formulation
US8846154B2 (en) 2005-06-07 2014-09-30 S.C. Johnson & Son, Inc. Carpet décor and setting solution compositions
US20100154146A1 (en) 2008-07-02 2010-06-24 S.C. Johnson & Son, Inc. Carpet decor and setting solution compositions
WO2007050543A3 (en) 2005-10-24 2007-09-07 Collegium Pharmaceutical Inc Topical pharmaceutical foam composition
CA2647127C (en) 2006-03-31 2015-10-06 Stiefel Research Australia Pty Ltd Foamable suspension gel
EP2041254B1 (en) * 2006-07-06 2012-11-07 Centennial Ventures BV Broad spectrum and skin friendly disinfecting composition
GB2443161B (en) * 2006-10-28 2011-03-23 Nupharm Lab Ltd Clobetasol spray
GB2443162B (en) * 2006-10-28 2011-02-09 Nupharm Lab Ltd Betamethasone spray
FR2911781B1 (en) 2007-01-26 2009-03-20 Fabre Pierre Dermo Cosmetique dermatological emulsion and method of preparing
DE102008006394A1 (en) * 2008-01-28 2009-07-30 Beiersdorf Ag Use of active compound complexes of panthenol, glycerine, citrate and / or bisabolol against pollen allergies
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US9480691B1 (en) * 2009-01-20 2016-11-01 Hill Dermaceuticals, Inc. Topical liquid containing refined peanut oil for treating skin proliferation or inflammation disorders
WO2011009972A1 (en) * 2009-07-21 2011-01-27 Zuazo Gauger, S.L. Foaming composition for creating indications for a limited duration of time
CN102665734A (en) * 2009-09-25 2012-09-12 法马索尔有限公司 Surface coatings for skin
CN101810566B (en) 2009-11-26 2012-06-20 天津金耀集团有限公司 Hydrocortisone butyrate cream
EP2335675B1 (en) 2009-12-10 2015-02-18 Neubourg Skin Care GmbH & Co. KG Emulsifier-free, polymer stabilised foam formulas
WO2011076208A3 (en) * 2009-12-22 2012-03-01 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
WO2012158405A3 (en) * 2011-05-16 2014-05-01 Pearlman Dale L Compositions and methods for the treatment of skin diseases
US8580286B2 (en) 2012-03-16 2013-11-12 Dale L. Pearlman Compositions and methods for the treatment of skin diseases
CA2842277A1 (en) 2011-07-20 2013-01-24 Perrigo Israel Pharmaceuticals Ltd Topical oily foam compositions
US9265727B1 (en) 2015-01-14 2016-02-23 Delcor Asset Corporation Spray foam corticosteroid product
US20170165275A1 (en) * 2015-12-15 2017-06-15 Therapeutics Inc. Halobetasol foam composition and method of use thereof

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018918A (en) 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
WO1985001876A1 (en) 1983-10-24 1985-05-09 Lockley Services Pty. Ltd. Foamable biocide composition
WO1986000196A1 (en) 1984-06-21 1986-01-16 Soltec Research Pty. Ltd. Aerosol product
WO1988004896A1 (en) 1987-01-08 1988-07-14 Soltec Research Pty. Ltd. Aerosol products
EP0331489A2 (en) 1988-03-03 1989-09-06 Parke Davis Pty. Ltd. Acne treatment
US4888354A (en) 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
EP0423695A2 (en) 1989-10-19 1991-04-24 Sterling Drug Inc. Aerosol composition for topical medicament
WO1992004419A1 (en) 1990-09-03 1992-03-19 Soltec Research Pty. Ltd. A concentrated aerosol space spray
WO1994016732A1 (en) 1993-01-20 1994-08-04 Soltec Research Pty. Ltd. Ectoparasiticidal formulation
WO1998023291A1 (en) 1996-11-22 1998-06-04 Soltec Research Pty. Ltd. Percutaneous delivery system
US5783202A (en) 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
WO1998052525A1 (en) 1997-05-20 1998-11-26 Soltec Research Pty. Ltd. Sunscreen composition
WO1999020250A1 (en) 1997-10-17 1999-04-29 Soltec Research Pty. Ltd. Topical antifungal composition
US5935554A (en) 1990-09-03 1999-08-10 Soltec Research Pty. Ltd. Concentrated aerosol space spray that is not an emulsion
WO1999053923A1 (en) 1998-04-22 1999-10-28 Soltec Research Pty. Ltd. Pharmaceutical composition
WO2000015193A1 (en) 1998-09-11 2000-03-23 Soltec Research Pty Ltd Mousse composition
WO2000066172A1 (en) 1999-04-29 2000-11-09 Soltec Research Pty. Ltd. Non-aqueous liquid shampoo composition
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69020900T2 (en) * 1989-07-28 1995-12-14 Hisamitsu Pharmaceutical Co Foam aerosol composition.
DE4446891A1 (en) * 1994-12-27 1996-07-04 Falk Pharma Gmbh A stable aqueous budesonide solution
CN1086575C (en) * 1995-06-27 2002-06-26 贝林格尔·英格海姆公司 New stable medicinal compositions for generating propellant-free aerosols

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018918A (en) 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
WO1985001876A1 (en) 1983-10-24 1985-05-09 Lockley Services Pty. Ltd. Foamable biocide composition
US4981678A (en) 1983-10-24 1991-01-01 Soltec Research Pty., Ltd. Foamable biocide composition
EP0160051B1 (en) 1983-10-24 1992-01-08 Lockley Services Pty. Ltd. Foamable biocide composition
US4915934A (en) 1983-10-24 1990-04-10 Tomlinson Roderick P J Foamable biocide composition
WO1986000196A1 (en) 1984-06-21 1986-01-16 Soltec Research Pty. Ltd. Aerosol product
WO1988004896A1 (en) 1987-01-08 1988-07-14 Soltec Research Pty. Ltd. Aerosol products
US4882182A (en) 1987-01-08 1989-11-21 Soltec Research Pty. Ltd. Aerosol product
US4888354A (en) 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
EP0331489A2 (en) 1988-03-03 1989-09-06 Parke Davis Pty. Ltd. Acne treatment
EP0423695A2 (en) 1989-10-19 1991-04-24 Sterling Drug Inc. Aerosol composition for topical medicament
US5935554A (en) 1990-09-03 1999-08-10 Soltec Research Pty. Ltd. Concentrated aerosol space spray that is not an emulsion
WO1992004419A1 (en) 1990-09-03 1992-03-19 Soltec Research Pty. Ltd. A concentrated aerosol space spray
US5516504A (en) 1990-09-03 1996-05-14 Soltec Research Pty. Ltd. Concentrated water-free aerosol space spray
EP1070752A2 (en) 1990-09-03 2001-01-24 Soltec Research Pty. Ltd. A concentrated aerosol space spray
WO1994016732A1 (en) 1993-01-20 1994-08-04 Soltec Research Pty. Ltd. Ectoparasiticidal formulation
US5783202A (en) 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
US6211250B1 (en) 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
WO1998023291A1 (en) 1996-11-22 1998-06-04 Soltec Research Pty. Ltd. Percutaneous delivery system
US6267949B1 (en) 1997-05-20 2001-07-31 Soltec Research Pty Ltd. Sunscreen composition
WO1998052525A1 (en) 1997-05-20 1998-11-26 Soltec Research Pty. Ltd. Sunscreen composition
WO1999020250A1 (en) 1997-10-17 1999-04-29 Soltec Research Pty. Ltd. Topical antifungal composition
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
WO1999053923A1 (en) 1998-04-22 1999-10-28 Soltec Research Pty. Ltd. Pharmaceutical composition
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6419913B1 (en) 1998-08-04 2002-07-16 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
WO2000015193A1 (en) 1998-09-11 2000-03-23 Soltec Research Pty Ltd Mousse composition
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2000066172A1 (en) 1999-04-29 2000-11-09 Soltec Research Pty. Ltd. Non-aqueous liquid shampoo composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Albert Zorko Abram and Roderick Peter John Tomlinson, Mousses, Chapter 19, pp. 221-232, Soltec Research Pty Ltd., Rowville, Victoria, Australia, Jun. 2001.
Timmens, P. and Gray, E., "The degradation of triamcinolone acetonide in aqueous solution: influence of the cyclic ketal function," J. Pharm. Pharmacol., 35:175-177 (1983).
Woodford, R. and Barry, B. W., "Bioavailability and Activity of Topical Corticosteroids from a Novel Drug Delivery System, the Aerosol Quick-Break Foam," J. Pharm. Sci., 66:99-103 (1977).
Yip and Po "The stability of betamethasone-17-valerate in semi-solid bases" J. Pharm. Pharmacol. 31, 400-402 (1979).

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233735A1 (en) * 1998-06-19 2006-10-19 Isabelle Preuilh Method for treating ailments of the scalp
US7316810B1 (en) 1998-06-19 2008-01-08 Galderma S.A. Foaming composition for washing and treating hair and/or scalp based on an active principle
US20080070878A1 (en) * 1998-06-19 2008-03-20 Galderma S.A. Foaming composition for washing and treating hair and/or scalp based on an active principle
US7700081B2 (en) 1998-06-19 2010-04-20 Galderma S.A. Foaming compositions for hair care
US8066976B2 (en) 1998-06-19 2011-11-29 Galderma S.A. Foaming compositions for hair care
US8066975B2 (en) 1998-06-19 2011-11-29 Galderma S.A. Foaming composition for washing and treating hair and/or scalp based on an active principle
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP3141246A1 (en) 2009-08-31 2017-03-15 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9364485B2 (en) 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9812179B2 (en) 2009-11-24 2017-11-07 Ovonyx Memory Technology, Llc Techniques for reducing disturbance in a semiconductor memory device
US8760906B2 (en) 2009-11-24 2014-06-24 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor memory device
US9561240B2 (en) 2012-12-26 2017-02-07 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
US9789106B2 (en) 2012-12-26 2017-10-17 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
WO2015044857A1 (en) 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Topical spray composition of halobetasol
WO2015044879A1 (en) 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Propellant-free topical spray composition of halobetasol
WO2015138650A1 (en) 2014-03-11 2015-09-17 Promius Pharma, LLC Topical corticosteroid compositions

Also Published As

Publication number Publication date Type
EP0813413B1 (en) 2003-11-05 grant
KR100427492B1 (en) 2004-07-15 grant
CA2214436C (en) 2007-11-20 grant
DK0813413T3 (en) 2004-03-15 grant
JP4557310B2 (en) 2010-10-06 grant
WO1996027376A1 (en) 1996-09-12 application
EP0813413A1 (en) 1997-12-29 application
CN1082817C (en) 2002-04-17 grant
ES2210349T3 (en) 2004-07-01 grant
DE69630593D1 (en) 2003-12-11 grant
DE69630593T2 (en) 2004-10-21 grant
DK813413T3 (en) grant
GB9504265D0 (en) 1995-04-19 grant
CA2214436A1 (en) 1996-09-12 application
US20030118511A1 (en) 2003-06-26 application
CN1179720A (en) 1998-04-22 application
US6126920A (en) 2000-10-03 grant
US20060171898A1 (en) 2006-08-03 application
JPH11501045A (en) 1999-01-26 application

Similar Documents

Publication Publication Date Title
US3929985A (en) Anhydrous candicidin foam compositions
US7029659B2 (en) Mousse composition
US6787529B2 (en) Topical composition
US5219877A (en) Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5597849A (en) Stick formulations for topical drug delivery of therapeutic agents and uses thereof
US8343945B2 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US5186925A (en) Nitroglycerin pump spray
US20100221194A1 (en) Topical foam composition
US6120752A (en) Medicinal aerosol products containing formulations of ciclesonide and related steroids
US4918065A (en) Corticoid-containing preparation for topical application
US6753013B1 (en) Pharmaceutical composition
US20120213710A1 (en) Non Surface Active Agent Non Polymeric Agent Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses
US5725874A (en) Solubilizer and external preparations containing the same
US20070154402A1 (en) Topical Pharmaceutical Foam Composition
US5104656A (en) Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
US4661524A (en) Topical treatment and composition
US5612327A (en) 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis
US20070059253A1 (en) Foamable pharmaceutical compositions and methods for treating a disorder
US4252796A (en) Stable water-in-oil emulsions
US5716609A (en) Therapeutic anti-inflammatory and analgesic composition containing nimesulide for use transdermally and a process for the manufacture thereof
US5658559A (en) Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5422361A (en) Stable cream and lotion bases for lipophilic drug compositions
US4185100A (en) Topical anti-inflammatory drug therapy
US5670547A (en) Moisturizing vehicle for topical application of vitamin A acid
US6962691B1 (en) Topical spray compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: CONNETICS AUSTRALIA PTY LTD, AUSTRALIA

Free format text: CHANGE OF NAME;ASSIGNOR:MEDEVA EUROPE PLC;REEL/FRAME:015286/0359

Effective date: 20030625

Owner name: CONNETICS AUSTRALIA PTY LTD., AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDEVA EUROPE PLC;REEL/FRAME:015286/0368

Effective date: 20030625

AS Assignment

Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD, AUSTRALIA

Free format text: CHANGE OF NAME;ASSIGNOR:CONNETICS AUSTRALIA PTY LTD;REEL/FRAME:019116/0391

Effective date: 20070326

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: STIEFEL WEST COAST, LLC, DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STIEFEL RESEARCH AUSTRALIA PTY LTD;REEL/FRAME:030511/0963

Effective date: 20130530

FPAY Fee payment

Year of fee payment: 8

FEPP

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)